OncoCyte Corporation (0KCC.L)
| Chiusura precedente | 3,4950 |
| Aperto | 2,3300 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 2,3300 - 2,3700 |
| Intervallo di 52 settimane | 2,3300 - 2,3700 |
| Volume | 5.814 |
| Media Volume | N/D |
| Capitalizzazione | 215,808M |
| Beta (5 anni mensile) | 1,75 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4170 |
| Prossima data utili | 09 nov 2021 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other biomarkers DetermaIO data in Triple Negative Breast Cancer published in a peer reviewed journal and confirmed in a randomized clinical trial study presented at ESMO; Evidence in fourth tumor type suggests pan-cancer utility DetermaRx test volume grows 65% year over year US transplant IP issued supp
- GlobeNewswire
Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test
DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has consistently proven to be more precise at identifying patients who are immunotherapy responders including those who may have been missed by PDL-1 IHC and other biomarkers IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with th
- GlobeNewswire
Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection
U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant Monitor facilitates fast and accurate testing of dd-cfDNA to allow for timely and confident post-transplant treatment decisions IRVINE, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes
